🎉 M&A multiples are live!
Check it out!

enGene Valuation Multiples

Discover revenue and EBITDA valuation multiples for enGene and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

enGene Overview

About enGene

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.


Founded

2023

HQ

United States of America
Employees

57

Website

engene.com

Financials

LTM Revenue n/a

LTM EBITDA -$84.6M

EV

$15.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

enGene Financials

enGene has a last 12-month revenue of n/a and a last 12-month EBITDA of -$84.6M.

In the most recent fiscal year, enGene achieved revenue of n/a and an EBITDA of -$52.0M.

enGene expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See enGene valuation multiples based on analyst estimates

enGene P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$94.8M -$52.0M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$24.5M -$99.9M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt $11.7M n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

enGene Stock Performance

As of April 15, 2025, enGene's stock price is $4.

enGene has current market cap of $204M, and EV of $15.2M.

See enGene trading valuation data

enGene Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$15.2M $204M XXX XXX XXX XXX $-1.71

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

enGene Valuation Multiples

As of April 15, 2025, enGene has market cap of $204M and EV of $15.2M.

enGene's trades at n/a LTM EV/Revenue multiple, and -0.2x LTM EBITDA.

Analysts estimate enGene's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for enGene and 10K+ public comps

enGene Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $15.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.2x XXX XXX XXX
P/E -3.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get enGene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

enGene Valuation Multiples

enGene's NTM/LTM revenue growth is n/a

enGene's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.

Over next 12 months, enGene's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate enGene's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for enGene and other 10K+ public comps

enGene Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -45% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

enGene Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

enGene M&A and Investment Activity

enGene acquired  XXX companies to date.

Last acquisition by enGene was  XXXXXXXX, XXXXX XXXXX XXXXXX . enGene acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by enGene

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About enGene

When was enGene founded? enGene was founded in 2023.
Where is enGene headquartered? enGene is headquartered in United States of America.
How many employees does enGene have? As of today, enGene has 57 employees.
Who is the CEO of enGene? enGene's CEO is Mr. Ronald H.W. Cooper.
Is enGene publicy listed? Yes, enGene is a public company listed on NAS.
What is the stock symbol of enGene? enGene trades under ENGN ticker.
When did enGene go public? enGene went public in 2023.
Who are competitors of enGene? Similar companies to enGene include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of enGene? enGene's current market cap is $204M
What is the current EBITDA of enGene? enGene's last 12-month EBITDA is -$84.6M.
What is the current EV/EBITDA multiple of enGene? Current EBITDA multiple of enGene is -0.2x.
Is enGene profitable? Yes, enGene is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.